Swedish biotech OncoZenge (Nasdaq: ONCOZ) has expanded its regulatory team as it prepares for a Phase III trial of BupiZenge ...

US private equity firm Vance Street Capital has expanded its life sciences manufacturing platform with the acquisition of ...

The US Food and Drug Administration (FDA) has approved Uplizna (inebilizumab-cdon) as the first and only treatment for adults ...

An Expert View from Dr Elena Wolff-Holz, global head of clinical development at Biocon Biologics, the biosimilar subsidiary ...

A planned autumn review of the UK’s 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) will be brought forward to report back in June, it has been announced.

Dark Blue Therapeutics, a UK discovery and development biotech developing precision oncology medicines, has announced the appointment of Edwin Moses as chairman.

US biotech MoonLake Immunotherapeutics (Nasdaq: MLTX) has entered into an agreement with Hercules Capital (NYSE: HTGC) for up to $500 million in non-dilutive capital, of which $75 million drawn down ...

US neuroscience-focused biopharma Neurocrine Biosciences (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani to the company's executive management team as chief medical officer (CMO) ...

Struggling US genomic medicines company Sangamo Therapeutics (Nasdaq: SGMO) has been offered a lifeline via a licensing deal ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wainzua (eplontersen) to treat adults with ...

Swiss pharma giant Roche’s Genentech subsidiary has presented new data at the AD/PD 2025 International Conference on ...

UK pharma major AstraZeneca (LSE: AZN) today reported extended approvals in Europe for two of its cancer drugs: Imfinzi ...